An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
NCT ID: NCT05097131
Last Updated: 2023-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
29 participants
OBSERVATIONAL
2021-11-18
2022-05-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
NCT05310071
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
NCT03639987
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
NCT04241068
A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)
NCT03668405
Study of AV-1959D, an Amyloid Beta Vaccine
NCT05642429
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All Participants
Participants who have been prescribed with aducanumab-avwa in the post-marketing setting according to standard care of practice will be enrolled.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant's treating physician has made the decision to initiate aducanumab-avwa prior to participant inclusion and independently of the purpose of the study.
Exclusion Criteria
* Participant has ever been treated with aducanumab-avwa at a dose of 3 milligrams per kilogram (mg/kg) or greater prior to signing ICF.
* Participant has ever been treated with aducanumab-avwa and discontinued treatment prior to signing ICF.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Biogen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Chula Vista, California, United States
Mehdi Meratee MD
Valencia, California, United States
Research Site
Boca Raton, Florida, United States
Research Site
Bradenton, Florida, United States
New Life Medical Research Center, Inc
Hialeah, Florida, United States
Miami Jewish Health System, Inc
Miami, Florida, United States
Imic, Inc.
Palmetto Bay, Florida, United States
Neurostudies, Inc
Port Charlotte, Florida, United States
Vero Beach Neurology and Research Institute
Vero Beach, Florida, United States
Northwest Neurology
Chicago, Illinois, United States
Research Site
Ozark, Missouri, United States
Las Vegas Medical Research
Las Vegas, Nevada, United States
South Shore Neurologic Associates, P.A.
Patchogue, New York, United States
Carolina Clinical Research & Consulting, LLC
Asheboro, North Carolina, United States
Research Site
Matthews, North Carolina, United States
Research Site
Canton, Ohio, United States
Dayton Center for Neurological Associates
Centerville, Ohio, United States
Center for Cognitive Health
Portland, Oregon, United States
Abington Neurological Associates
Abington, Pennsylvania, United States
Coastal Neurology, PA
Port Royal, South Carolina, United States
Genesis Neuroscience Clinic
Knoxville, Tennessee, United States
The Memory Clinic
Bennington, Vermont, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
US-ALZ-11855
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.